Imaging Core

成像核心

• 批准号: 7670958
• 负责人: Mark A. Mintun
• 金额: $ 72.96万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-15 至 2014-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7670958
• 关键词: Alzheimer' s Disease; Amyloid; Amyloid Proteins; Amyloid beta-Protein; Amyloid deposition; Anatomy; Archives; Binding; Binding Sites; Biochemical; Biological; Biological Markers; Brain; Brain Injuries; Brain imaging; Cells; Clinical; Collection; Data; Data Set; Databases; Decision Making; Dementia; Deposition; Disease; Evaluation; Functional disorder; Generations; Goals; Hand; Head; Image; Imaging Techniques; Individual; Informatics; Intervention; Late Onset Alzheimer Disease; Magnetic Resonance Imaging; Measures; Metabolic; Metabolism; Morphologic artifacts; Neuronal Dysfunction; Neurons; Noise; Participant; Positron-Emission Tomography; Procedures; Process; Protocols documentation; Psychometrics; Qualifying; Quality Control; Quarantine; Recruitment Activity; Relative (related person); Research Personnel; Resolution; Role; Scanning; Senile Plaques; Series; Signal Transduction; Site; Staging; Standardization; Standards of Weights and Measures; Testing; Time; Work; abeta accumulation; brain tissue; brain volume; density; design; glucose metabolism; gray matter; image processing; insight; interest; neuroimaging; pre-clinical; relating to nervous system

We hypothesize that Alzheimer's disease (AD) has a preclinical stage in which elevated levels of brain amyloid protein and accumulation of beta-amyloid deposits foreshadow the gradual onset of neuronal dysfunction, cell loss and dementia. While the exact role of amyloid in the initiation of brain damage is still unclear, clarifying the exact timing of amyloid deposition that precede AD would be extremely helpful in understanding the biological origins of AD and in designing appropriate interventions. Brain imaging provides a window into many of the hypothesized biochemical, functional and anatomic changes in AD. With Positron Emission Tomography (PET) using [11C]PIB it is possible to estimate the density of beta-amyloid plaques by imaging the PIB binding sites. With PET using [18F]FDG it is possible to estimate neuronal function from measures of metabolic activity. Finally, with magnetic resonance imaging (MRI) volume loss over time can be quantified in regional and global brain measures. It is our premise that by examining the temporal and spatial interrelationships between these three measures important insights will be gained in the pathophysiology of AD. The value of these imaging biomarkers are further enhanced by combining the data with CSF biomarkers and clinical and psychometric data. Towards these goals, the Imaging Core will provide two key support activities to the DIAN effort: Aim 1: Oversee the collection of all image data. This data includes MR scans for morphometrics, PET FDG scans for metabolism and PET PIB scans for imaging beta-amyloid plaques. Aim 2: Perform image processing and analysis to extract biologically relevant measures from the image data set. These measures include whole brain volume and cortical and subcortical regional measures of gray matter volume, relative glucose metabolism and PIB-derived estimates of beta-amyloid plaque deposition.

我们假设阿尔茨海默氏病（AD）具有临床前阶段，其中大脑水平升高 淀粉样蛋白和β-淀粉样蛋白沉积物的积累预示了神经元的逐渐发作 功能障碍，细胞丧失和痴呆。淀粉样蛋白在开始脑损伤中的确切作用仍然是 尚不清楚，阐明AD之前的淀粉样沉积的确切时机将非常有帮助 了解AD的生物学起源以及设计适当的干预措施。大脑成像提供 AD中许多假设的生化，功能和解剖变化的窗口。带有正面 发射断层扫描（PET）使用[11C] PIB，可以通过估计β-淀粉样木质斑块的密度 成像PIB结合位点。使用PET使用[18F] FDG，可以从 代谢活性的度量。最后，随着磁共振成像（MRI）量损失，随着时间的流逝可以 在区域和全球大脑测量中进行量化。我们的前提是通过检查时间和 这三个措施之间的空间相互关系将在其中获得重要的见解 AD的病理生理学。 通过将数据与CSF生物标志物相结合，进一步增强了这些成像生物标志物的价值 以及临床和心理测量数据。朝向这些目标，成像核心将提供两个关键的支持 Dian努力的活动：目标1：监督所有图像数据的收集。该数据包括MR扫描 对于形态计量学，PET FDG扫描代谢和PET PIB扫描以成像β-淀粉样蛋白斑块。 目标2：执行图像处理和分析以从图像数据中提取与生物学相关的措施 放。这些措施包括灰色的全脑体积以及皮质和皮层下区域测量 物质体积，相对的葡萄糖代谢和PIB衍生的β-淀粉样菌斑沉积的估计值。